Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Basilea Pharmaceutica has unveiled positive results from a double-blind randomized Phase I study of antibiotic BAL30072, which demonstrated that the drug was safe and well tolerated at all dose levels.
Subscribe to our email newsletter
BAL30072, a novel siderophore (iron-binding) sulfactam antibiotic, was developed for the patients who were suffering from infections caused by multidrug-resistant Gram-negative bacteria.
The Phase I study assessed the safety, tolerability and pharmacokinetics of single ascending doses of BAL30072 in healthy volunteers.
The trial results also demonstrated dose-proportional plasma levels as well as linear pharmacokinetic properties.
Basilea CEO Anthony Man said these results support the potential of BAL30072 as a new treatment option for severe and life- threatening infections caused by multidrug-resistant Gram-negative bacteria, where currently very limited therapeutic options exist.